High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies

Jill A. Moormeier*, Stephanie F. Williams, Lynne S. Kaminer, Miriam Garner, Jacob D. Bitran

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Forty patients with refractory solid tumors or non-Hodgkin's lymphoma were treated with high-dose cyclophosphamide, thiotepa, and carmustine (BCNU), followed by autologous stem cell rescue, in a phase I does escalation study. The dose-limiting toxic effect was delayed drug-induced pulmonary disease, seen in three patients who received 660-750mg of BCNU/m2in combination with cyclophosphamide and thitepa. The early death rate due to toxic effects was 20%; all deaths were attributed to sepsis or respiratory failure. The overall response rate was 63%. The median time to disease progression was 14 weeks. Although this regimen provided effective cytoreduction, its use in heavily pretreated patients with bulky disease is of limited value. [J Natl Cancer Inst 82:29-34,1990]

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalJournal of the National Cancer Institute
Volume82
Issue number1
DOIs
StatePublished - Jan 3 1990
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies'. Together they form a unique fingerprint.

Cite this